No Data
Immunic Eyes Key Data Readout From Multiple Sclerosis Trial in 2025 | NASDAQ:IMUX
Express News | D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target
Press Release: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX
Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6